AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25262475 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 µg/kg
Number of subjects: 41
Study 25262475 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 41
Study 23754254 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus‐eluting stents (EES; Xience)
Number of subjects: 377
Study 23754254 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus‐eluting stents (SES; Cypher)
Number of subjects: 377
Study 21575503 — intervention group
Group type: EXPERIMENTAL
Intervention: CPT‐11 + CAP (irinotecan 100 mg/m² on days 1 and 8; capecitabine 2000 mg/m² bid for 14 days, repeated every 21 days)
Number of subjects: 63
Study 21575503 — intervention group
Group type: COMPARATOR
Intervention: L‐OHP + CAP (oxaliplatin 100 mg/m² on day 1; capecitabine 2000 mg/m² bid for 14 days, repeated every 21 days)
Number of subjects: 63
Study 18650513 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir
Number of subjects: 462
Study 18650513 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 462
Study 18650513 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir with darunavir or enfuvirtide
Number of subjects: 462
Study 18650513 — intervention group
Group type: COMPARATOR
Intervention: Placebo with darunavir or enfuvirtide
Number of subjects: 462
Study 16567600 — intervention group
Group type: EXPERIMENTAL
Intervention: Disclosure intervention (mailed compensation disclosure letter)
Number of subjects: 8000
Study 12626469 — intervention group
Group type: EXPERIMENTAL
Intervention: High carbohydrate availability (HC) - 9.32 +/- 0.08 g.kg(-1).day(-1)
Number of subjects: 6
Study 12626469 — intervention group
Group type: COMPARATOR
Intervention: Low carbohydrate availability (LC) - 0.59 +/- 0.21 g.kg(-1).day(-1)
Number of subjects: 6
Study 12626469 — intervention group
Group type: EXPERIMENTAL
Intervention: Low carbohydrate availability (LC)
Number of subjects: 6
Study 12626469 — intervention group
Group type: COMPARATOR
Intervention: High carbohydrate availability (HC)
Number of subjects: 6
Study 11111812 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange (PE) therapy using fresh frozen plasma
Number of subjects: 0
Study 11111812 — intervention group
Group type: COMPARATOR
Intervention: Cryosupernatant
Number of subjects: 0
Study 9074537 — intervention group
Group type: EXPERIMENTAL
Intervention: Active chronic cocaine users
Number of subjects: 15
Study 9074537 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 15
Study 8403637 — intervention group
Group type: EXPERIMENTAL
Intervention: Ilizarov external fixator with gentamicin methylmethacrylate bead (GMB) and intravenous antibiotics (Group 2)
Number of subjects: 18
Study 8403637 — intervention group
Group type: COMPARATOR
Intervention: Ilizarov external fixator with initial debridement and intravenous antibiotics (Group 1)
Number of subjects: 18
Study 3510323 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous saphenous vein (ASV) grafts to the popliteal artery
Number of subjects: 845
Study 3510323 — intervention group
Group type: COMPARATOR
Intervention: Polytetrafluoroethylene (PTFE) grafts to the popliteal artery
Number of subjects: 845
Study 3510323 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous saphenous vein (ASV) grafts above-knee
Number of subjects: 845
Study 3510323 — intervention group
Group type: COMPARATOR
Intervention: Polytetrafluoroethylene (PTFE) grafts above-knee
Number of subjects: 845
Study 3510323 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous saphenous vein (ASV) grafts below-knee
Number of subjects: 845
Study 3510323 — intervention group
Group type: COMPARATOR
Intervention: Polytetrafluoroethylene (PTFE) grafts below-knee
Number of subjects: 845
Study 3510323 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous saphenous vein (ASV) grafts infrapopliteal
Number of subjects: 845
Study 3510323 — intervention group
Group type: COMPARATOR
Intervention: Polytetrafluoroethylene (PTFE) grafts infrapopliteal
Number of subjects: 845
Study 3510323 — intervention group
Group type: COMPARATOR
Intervention: Obligatory infrapopliteal PTFE grafts
Number of subjects: 845
Study 29148345 — intervention group
Group type: EXPERIMENTAL
Intervention: Executive functioning
Number of subjects: 440
Study 29124500 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based unguided self-help psychosocial intervention (BADI)
Number of subjects: 284
Study 29124500 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 284
Study 26296448 — intervention group
Group type: EXPERIMENTAL
Intervention: IR/ER OC/APAP
Number of subjects: 1106
Study 26296448 — intervention group
Group type: COMPARATOR
Intervention: IR OC/APAP
Number of subjects: 1106
Study 26296448 — intervention group
Group type: COMPARATOR
Intervention: IR tramadol HCl/APAP
Number of subjects: 1106
Study 26296448 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1106
Study 26054181 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate ProClinical C200 toothbrush with triple clean head
Number of subjects: 120
Study 26054181 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate ProClinical C200 toothbrush with sensitive head
Number of subjects: 120
Study 26054181 — intervention group
Group type: COMPARATOR
Intervention: Manual flat‐trim toothbrush (Oral B Indicator toothbrush)
Number of subjects: 120
Study 21847569 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2140023 monohydrate 40 mg orally twice daily for 14 days
Number of subjects: 16
Study 21847569 — intervention group
Group type: COMPARATOR
Intervention: LY404039 (single intraperitoneal injection)
Number of subjects: 16
Study 21847569 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2140023 monohydrate (acute dosing)
Number of subjects: 16
Study 21847569 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2140023 monohydrate (dosed for 7 days)
Number of subjects: 16
Study 19806426 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAID plaster
Number of subjects: 165
Study 19806426 — intervention group
Group type: COMPARATOR
Intervention: Oral NSAIDs
Number of subjects: 165
Study 17662919 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet intervention
Number of subjects: 30
Study 17662919 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 16416370 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral to the specialized pediatric nephrology unit within the first year of life
Number of subjects: 43
Study 16416370 — intervention group
Group type: COMPARATOR
Intervention: Referral to the specialized pediatric nephrology unit after the first year of life
Number of subjects: 43
Study 12571526 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype informed consent process
Number of subjects: 4892
Study 12571526 — intervention group
Group type: COMPARATOR
Intervention: Baseline knowledge
Number of subjects: 4892
Study 10408998 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed reminders (sent at 3 weeks after the visit)
Number of subjects: 200
Study 10408998 — intervention group
Group type: COMPARATOR
Intervention: Control group (no reminders)
Number of subjects: 200
Study 8887291 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flux polysulfone hemodialysis (HfPS-HD)
Number of subjects: 380
Study 8887291 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flux polysulfone hemodiafiltration (HfPS-HDF)
Number of subjects: 380
Study 8887291 — intervention group
Group type: COMPARATOR
Intervention: Cuprophan hemodialysis (Cu-HD)
Number of subjects: 380
Study 8887291 — intervention group
Group type: COMPARATOR
Intervention: Low-flux polysulfone hemodialysis (LfPS-HD)
Number of subjects: 380
Study 1857139 — intervention group
Group type: EXPERIMENTAL
Intervention: Group practice model
Number of subjects: 0
Study 1857139 — intervention group
Group type: COMPARATOR
Intervention: Ongoing randomization
Number of subjects: 0
Study 6352780 — intervention group
Group type: COMPARATOR
Intervention: Albuterol (inhalations from a metered dose inhaler) - 1, 2, 4, 6, and 8 inhalations
Number of subjects: 44
Study 6352780 — intervention group
Group type: COMPARATOR
Intervention: Albuterol (delivered by IPPB) - 1.25, 2.5, 5, 10, and 15 mg
Number of subjects: 44
Study 30316200 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Number of subjects: 0
Study 30316200 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30356287 — intervention group
Group type: EXPERIMENTAL
Intervention: ART (Antiretroviral Treatment)
Number of subjects: 12610
Study 30356287 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent HIV infections (ARV-naïve individuals with detectable HIV-1 RNA >400 copies/mL)
Number of subjects: 12610
Study 30356287 — intervention group
Group type: EXPERIMENTAL
Intervention: Annualized HIV incidence (overall population)
Number of subjects: 12610
Study 30356287 — intervention group
Group type: EXPERIMENTAL
Intervention: Annualized HIV incidence (younger subset 16–49 years)
Number of subjects: 12610
Study 27138295 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol extended release (ER) 25 to 100 mg
Number of subjects: 75
Study 24506852 — intervention group
Group type: COMPARATOR
Intervention: Modified surviving sepsis bundles group (n=42) with PiCCO catheter and fluid resuscitation guided by ITBVI (850-1000 mL/m²), dobutamine for heart function, norepinephrine for MAP maintenance, and monitoring of extra-vascular lung water.
Number of subjects: 82
Study 24506852 — intervention group
Group type: COMPARATOR
Intervention: Standard surviving sepsis bundle group (n=40) receiving standard EGDT bundles.
Number of subjects: 82
Study 22139005 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenon anaesthesia
Number of subjects: 42
Study 22139005 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane anaesthesia
Number of subjects: 42
Study 20236862 — intervention group
Group type: EXPERIMENTAL
Intervention: Human menopausal gonadotrophin or follicle‐stimulating hormone following the long gonadotrophin‐releasing hormone agonist protocol
Number of subjects: 731
Study 20236862 — intervention group
Group type: EXPERIMENTAL
Intervention: Best predictive model using age, duration of infertility, infertility diagnosis, endometrial thickness, pre‐stimulation total testosterone and sex hormone‐binding globulin concentrations
Number of subjects: 731
Study 17561808 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower body muscle tensing (LBMT)
Number of subjects: 20
Study 15853445 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral moxifloxacin
Number of subjects: 12231
Study 15853445 — intervention group
Group type: COMPARATOR
Intervention: Comparator antibacterial (cefuroxime, clarithromycin)
Number of subjects: 12231
Study 12109763 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent information reliance
Number of subjects: 0
Study 12109763 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative judgment
Number of subjects: 0
Study 10703404 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-based designated requestor program (8-hour training)
Number of subjects: 13
Study 10703404 — intervention group
Group type: COMPARATOR
Intervention: Organ procurement coordinator approach
Number of subjects: 13
Study 7580666 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback of information on control of asthma
Number of subjects: 818
Study 7580666 — intervention group
Group type: COMPARATOR
Intervention: No feedback (control group)
Number of subjects: 818
Study 2270531 — intervention group
Group type: COMPARATOR
Intervention: Intravenous heparin sodium by continuous infusion for 6-10 days
Number of subjects: 271
Study 2270531 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous heparin calcium, intermittent for 6-10 days
Number of subjects: 271
Study 6258959 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline sulphate aerosol (1.0‐1.25 mg)
Number of subjects: 7
Study 6258959 — intervention group
Group type: COMPARATOR
Intervention: Placebo aerosol
Number of subjects: 7
Study 6258959 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 7
Study 31924771 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene expression levels in multiple tissues
Number of subjects: 0
Study 31924771 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue-specific associations
Number of subjects: 0
Study 31924771 — intervention group
Group type: EXPERIMENTAL
Intervention: Causal pathways for trait-associated variants
Number of subjects: 0
Study 31924771 — intervention group
Group type: EXPERIMENTAL
Intervention: Putative associations at loci
Number of subjects: 0
Study 31036336 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive strategy with stepwise selection for cholecystectomy
Number of subjects: 1067
Study 31036336 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1067
Study 31036336 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive strategy
Number of subjects: 1067
Study 27575013 — intervention group
Group type: EXPERIMENTAL
Intervention: Denneroll™ cervical traction
Number of subjects: 72
Study 27575013 — intervention group
Group type: COMPARATOR
Intervention: Multimodal program without Denneroll™ cervical traction
Number of subjects: 72
Study 27007068 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg/d etoricoxib
Number of subjects: 0
Study 27007068 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25081826 — intervention group
Group type: EXPERIMENTAL
Intervention: PAS 400 (400 mg PS & 400 mg PA per day)
Number of subjects: 75
Study 25081826 — intervention group
Group type: EXPERIMENTAL
Intervention: PAS 200 (200 mg PS & 200 mg PA per day)
Number of subjects: 75
Study 25081826 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 22322124 — intervention group
Group type: EXPERIMENTAL
Intervention: Single cleansing with chlorhexidine
Number of subjects: 29760
Study 22322124 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple cleansing with chlorhexidine
Number of subjects: 29760
Study 22322124 — intervention group
Group type: COMPARATOR
Intervention: Dry cord care
Number of subjects: 29760
Study 19531605 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive rehabilitation robot (n = 15)
Number of subjects: 27
Study 19531605 — intervention group
Group type: COMPARATOR
Intervention: Passive motion device (n = 12)
Number of subjects: 27
Study 17973637 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-HT(3) antagonist ondansetron given orally
Number of subjects: 22
Study 17973637 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 22
Study 15297089 — intervention group
Group type: EXPERIMENTAL
Intervention: High-contrast red tableware (intervention)
Number of subjects: 9
Study 15297089 — intervention group
Group type: EXPERIMENTAL
Intervention: High-contrast blue tableware (follow-up intervention)
Number of subjects: 9
Study 15297089 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-contrast red and low-contrast blue tableware (follow-up interventions)
Number of subjects: 9
Study 15297089 — intervention group
Group type: COMPARATOR
Intervention: Baseline (white tableware)
Number of subjects: 9
Study 11337927 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous bolus of mt‐PA (monteplase) 15,000 IU/kg
Number of subjects: 46
Study 11337927 — intervention group
Group type: COMPARATOR
Intervention: No mt‐PA (control group)
Number of subjects: 46
Study 9447279 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist therapy for 6 months
Number of subjects: 11
Study 8941780 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen effervescent granules 600 mg (Brufen Granules)
Number of subjects: 100
Study 8941780 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen tablets 600 mg
Number of subjects: 100
Study 3115228 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 90
Study 3115228 — intervention group
Group type: COMPARATOR
Intervention: Moxalactam
Number of subjects: 90
Study 3115228 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin and Moxalactam
Number of subjects: 90
Study 30218062 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of 200,000 IU vitamin D3
Number of subjects: 117
Study 30218062 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 27096709 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine lipogel, 2.0% w/w
Number of subjects: 38
Study 27096709 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate cream, 0.05% w/w
Number of subjects: 38
Study 27096709 — intervention group
Group type: COMPARATOR
Intervention: Conventional cyclosporine cream, 2.0% w/w
Number of subjects: 38
Study 27096709 — intervention group
Group type: COMPARATOR
Intervention: Placebo lipogel
Number of subjects: 38
Study 26292178 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual cognitive stimulation therapy (iCST)
Number of subjects: 273
Study 26292178 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 273
Study 24228534 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune 1 combined HAART
Number of subjects: 228
Study 24228534 — intervention group
Group type: COMPARATOR
Intervention: Placebo combined HAART
Number of subjects: 228
Study 21395575 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 34
Study 21395575 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 18363913 — intervention group
Group type: EXPERIMENTAL
Intervention: Q-switched Nd:YAG laser 532 nm
Number of subjects: 20
Study 18363913 — intervention group
Group type: EXPERIMENTAL
Intervention: Q-switched Nd:YAG laser 1064 nm
Number of subjects: 20
Study 14627758 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized counseling for diet and exercise over 24 months
Number of subjects: 48
Study 14627758 — intervention group
Group type: COMPARATOR
Intervention: No psychiatric diagnosis
Number of subjects: 48
Study 10934552 — intervention group
Group type: EXPERIMENTAL
Intervention: Halofantrine
Number of subjects: 0
Study 10934552 — intervention group
Group type: COMPARATOR
Intervention: Quinine-Fansidar
Number of subjects: 0
Study 8779651 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid fortification in flour
Number of subjects: 0
Study 8779651 — intervention group
Group type: COMPARATOR
Intervention: No intervention (current situation without fortification)
Number of subjects: 0
Study 2095341 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin stearate (ES) 1000 mg
Number of subjects: 11
Study 2095341 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin acistrate (EA) 800 mg
Number of subjects: 11
Study 2095341 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 81243 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal injection of synthetic substance P (10(‐7)‐‐10(‐5) M)
Number of subjects: 0
Study 81243 — intervention group
Group type: COMPARATOR
Intervention: Oral pretreatment with chlorcyclizine (antihistaminic drug)
Number of subjects: 0
Study 81243 — intervention group
Group type: COMPARATOR
Intervention: Local pretreatment with Compound 48/80
Number of subjects: 0
Study 81243 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance P
Number of subjects: 0
Study 31050685 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised Perceived Stress Scale (PSS-14)
Number of subjects: 367
Study 27683800 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab (open-label) every 4 weeks
Number of subjects: 532
Study 27683800 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased dosing to vedolizumab every 4 weeks (from every 8 weeks)
Number of subjects: 532
Study 27683800 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab (every 4 weeks)
Number of subjects: 532
Study 26372493 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric anesthesia procedures
Number of subjects: 486900
Study 24195823 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-drainage group
Number of subjects: 272
Study 24195823 — intervention group
Group type: COMPARATOR
Intervention: Drainage group
Number of subjects: 272
Study 24195823 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 272
Study 21346163 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased systolic blood pressure (SBP) variability outside a range of 75 to 135 mm Hg intraoperatively and 85 to 145 mm Hg pre- and postoperatively.
Number of subjects: 1512
Study 21346163 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk patients with SBP variability
Number of subjects: 1512
Study 21346163 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk patients with SBP variability
Number of subjects: 1512
Study 19838998 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (133 mg or 200 IUs)
Number of subjects: 14
Study 19838998 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-supplemented subjects)
Number of subjects: 14
Study 16685705 — intervention group
Group type: EXPERIMENTAL
Intervention: Tree-type method for estimating baseline hazards and covariate effects with time-dependent covariates
Number of subjects: 0
Study 16685705 — intervention group
Group type: COMPARATOR
Intervention: Traditional proportional hazard model
Number of subjects: 0
Study 14987324 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon plus ribavirin combination therapy
Number of subjects: 0
Study 14987324 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline serum interferon-gamma-inducible protein-10 levels greater than 299 pg/mL
Number of subjects: 0
Study 14987324 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline serum interferon-gamma-inducible protein-10 levels lower than 299 pg/mL
Number of subjects: 0
Study 14987324 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased serum interferon-gamma-inducible protein-10 levels at baseline
Number of subjects: 0
Study 11476461 — intervention group
Group type: EXPERIMENTAL
Intervention: Pranlukast (225 mg twice daily) in group 1p (N = 14)
Number of subjects: 63
Study 11476461 — intervention group
Group type: EXPERIMENTAL
Intervention: Pranlukast (225 mg twice daily) in group 2p (N = 14)
Number of subjects: 63
Study 11476461 — intervention group
Group type: EXPERIMENTAL
Intervention: Pranlukast (225 mg twice daily) in group 3p (N = 11)
Number of subjects: 63
Study 11476461 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy in groups 1c, 2c, and 3c (N = 24)
Number of subjects: 63
Study 9489812 — intervention group
Group type: EXPERIMENTAL
Intervention: Community based physical therapy (PT) program, at least 4 visits or 3 hours of PT over 6 weeks
Number of subjects: 150
Study 9489812 — intervention group
Group type: COMPARATOR
Intervention: Wait list control group (CG)
Number of subjects: 150